A 29-Year-Old CEO Who's Shaking Up Diagnostics & Other Stories From The 2019 Healthcare 30 Under 30

When 29-year-old Stanford biology Ph.D. Trevor Martin decided to start a company, that meant wanting to create diagnostic tests, not drugs. To do that, Martin happened upon one of the hottest technologies in biotech: an enzyme called CRISPR.